Quantitative proteomics analysis reveals BAG3 as a potential target to suppress severe acute respiratory syndrome coronavirus replication.
The discovery of a novel coronavirus (CoV) as the causative agent of severe acute respiratory syndrome (SARS) has highlighted the need for a better understanding of CoV replication. The replication of SARS-CoV is highly dependent on host cell factors. However, relatively little is known about the cellular proteome changes that occur during SARS-CoV replication. Recently, we developed a cell line expressing a SARS-CoV subgenomic replicon and used it to screen inhibitors of SARS-CoV replication. To identify host proteins important for SARS-CoV RNA replication, the protein profiles of the SARS-CoV replicon cells and parental BHK21 cells were compared using a quantitative proteomic strategy termed "stable-isotope labeling by amino acids in cell culture-mass spectrometry" (SILAC-MS). Our results revealed that, among the 1,081 host proteins quantified in both forward and reverse SILAC measurements, 74 had significantly altered levels of expression. Of these, significantly upregulated BCL2-associated athanogene 3 (BAG3) was selected for further functional studies. BAG3 is involved in a wide variety of cellular processes, including cell survival, cellular stress response, proliferation, migration, and apoptosis. Our results show that inhibition of BAG3 expression by RNA interference led to significant suppression of SARS-CoV replication, suggesting the possibility that upregulation of BAG3 may be part of the machinery that SARS-CoV relies on for replication. By correlating the proteomic data with these functional studies, the findings of this study provide important information for understanding SARS-CoV replication.
Zhang
Liang
L
Division of Research, Singapore Health Research Facilities, 7 Hospital Drive, Singapore 169611, Republic of Singapore.
Zhang
Zhi-Ping
ZP
Zhang
Xian-En
XE
Lin
Fu-Sen
FS
Ge
Feng
F
D048868:Adaptor Proteins, Signal Transducing / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D002460:Cell Line; D002522:Chlorocebus aethiops; D006224:Cricetinae; D006801:Humans; D040901:Proteomics; D045473:Severe acute respiratory syndrome-related coronavirus / Q000235:genetics / Q000502:physiology*; D045169:Severe Acute Respiratory Syndrome / Q000235:genetics / Q000378:metabolism* / Q000821:virology; D014709:Vero Cells; D014779:Virus Replication
D048868:Adaptor Proteins, Signal Transducing
Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15764-9
14671320
FEBS Lett. 2006 Mar 6;580(6):1531-5
16494877
Virology. 1998 Jul 5;246(2):288-97
9657947
Virology. 2007 Mar 30;360(1):150-8
17098272
Cell Microbiol. 2010 Jan;12(1):10-8
19888990
EMBO J. 2009 Apr 8;28(7):889-901
19229298
Mol Cell Proteomics. 2002 May;1(5):376-86
12118079
Biochem Biophys Res Commun. 2006 Aug 18;347(1):261-5
16808902
Nat Biotechnol. 2004 Sep;22(9):1139-45
15314609
J Gen Virol. 2008 Apr;89(Pt 4):866-877
18343826
J Virol. 2007 Jul;81(14):7491-503
17475647
N Engl J Med. 2003 May 15;348(20):1953-66
12690092
Leukemia. 2004 Feb;18(2):358-60
14628070
Mol Cell Proteomics. 2005 Jul;4(7):902-13
15784933
J Virol. 2005 May;79(10):6180-93
15858003
J Biol Chem. 2006 Oct 6;281(40):30269-78
16895903
J Biol Chem. 2003 Aug 1;278(31):28490-500
12750378
Antiviral Res. 2008 Nov;80(2):107-13
18584889
Curr Top Dev Biol. 2005;67:285-303
15949538
J Virol. 2003 Aug;77(15):8181-6
12857886
Annu Rev Pharmacol Toxicol. 2000;40:617-47
10836149
J Virol. 2004 Dec;78(24):13600-12
15564471
Autophagy. 2007 Nov-Dec;3(6):581-5
17700057
J Proteome Res. 2008 Sep;7(9):3847-59
18646787
Curr Opin Microbiol. 2004 Aug;7(4):412-9
15358261
J Cell Sci. 2007 Apr 1;120(Pt 7):1149-52
17376960
Nat Struct Mol Biol. 2009 Nov;16(11):1134-40
19838190
Mol Cell Biol. 2004 Feb;24(4):1779-90
14749392
Curr Top Microbiol Immunol. 2009;335:323-33
19802573
Curr Top Microbiol Immunol. 2009;335:267-85
19802570
Expert Rev Proteomics. 2007 Dec;4(6):815-29
18067418
Clin Infect Dis. 2004 May 15;38(10):1420-7
15156481
Int J Biochem Cell Biol. 2007;39(7-8):1337-42
17493862
J Virol. 2004 Sep;78(18):9977-86
15331731
J Biol Chem. 2009 Feb 27;284(9):5523-32
19114712
Rev Med Virol. 2009 Nov;19(6):359-78
19750559
J Virol. 2001 Jul;75(14):6402-9
11413307
Brief Funct Genomic Proteomic. 2006 Dec;5(4):261-72
16772273
Microbiol Mol Biol Rev. 2007 Jun;71(2):398-411
17554050
Exp Cell Res. 2006 Sep 10;312(15):2962-71
16859681
J Virol. 2002 Sep;76(17):8560-71
12163576
J Gen Virol. 2003 Sep;84(Pt 9):2305-2315
12917450
Crit Rev Biotechnol. 2007 Apr-Jun;27(2):63-75
17578703
Curr Biol. 2003 Dec 2;13(23):2037-44
14653992
J Biol Chem. 2008 Jan 18;283(3):1437-1444
18006506
Nat Methods. 2008 Apr;5(4):319-22
18345006
J Cell Physiol. 2009 Feb;218(2):264-7
18821563
Semin Cancer Biol. 2006 Jun;16(3):162-72
16678438
Biochim Biophys Acta. 2005 Jun 30;1741(1-2):4-10
15916886
Science. 2005 Jun 3;308(5727):1472-7
15933201
Curr Top Dev Biol. 2005;65:211-28
15642385
Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20912-7
19088197
J Biol Chem. 2004 Mar 12;279(11):10136-41
14699140
Nucleic Acids Res. 2007 Jan;35(Database issue):D247-52
17130144
Proteomics. 2006 Oct;6(20):5628-36
16991198
J Virol. 2006 Jun;80(12):5927-40
16731931
Cell Mol Life Sci. 2008 May;65(9):1390-402
18264803
Adv Exp Med Biol. 2006;581:85-8
17037509
Curr Opin Gastroenterol. 2009 Nov;25(6):512-20
19826372
Microbes Infect. 2005 Feb;7(2):248-59
15777647
J Gen Virol. 2009 Jul;90(Pt 7):1629-1640
19282432
Proteomics. 2008 Dec;8(23-24):5108-18
19016532
PLoS Pathog. 2008 May 02;4(5):e1000054
18451981
J Proteome Res. 2004 May-Jun;3(3):549-55
15253436
Proteomics. 2004 Jul;4(7):1985-8
15221759
Science. 2003 May 30;300(5624):1399-404
12730501
Curr Top Microbiol Immunol. 2009;335:1-32
19802558
J Proteome Res. 2010 Mar 5;9(3):1549-64
20070120
Cancer Lett. 2002 Dec 15;188(1-2):25-32
12406544